ACP Demands FDA Premarket Review of Supplements in Major Policy Shift

The American College of Physicians (ACP), one of the nation's largest medical specialty organizations representing 161,000 internal medicine physicians, has issued a comprehensive position paper calling for fundamental changes to how dietary supplements are regulated in the United States. The organization's recommendation to require FDA premarket safety review of supplements represents one of the most significant challenges to the 1994 Dietary Supplement Health and Education Act (DSHEA) framework in three decades.

If implemented, the policy shift would require supplement manufacturers to obtain FDA approval before bringing products to market—a dramatic departure from the current post-market surveillance model that has governed the industry since DSHEA's passage. The proposal comes as the dietary supplement industry has grown to an estimated $159 billion in annual revenue, with thousands of products reaching consumers without pre-sale safety evaluation.

The Case for Regulatory Reform

The ACP's position paper highlights several areas of concern that have emerged under the current regulatory framework. Between 2004 and 2021, the FDA received 79,071 adverse event reports related to dietary supplements, according to data cited in industry discussions. While adverse event reporting is voluntary and likely represents significant underreporting, the numbers have raised questions about post-market surveillance effectiveness.

Research has documented concerning quality control issues across the supplement industry:

• Studies have found contamination rates ranging from 12% to 58% in various product categories
• Adulteration with undeclared pharmaceutical ingredients remains a persistent problem
• Heavy metal contamination has been detected in products marketed for children and pregnant women
• Label accuracy issues continue to affect product categories from herbal supplements to sports nutrition products

The ACP is also calling for implementation of United States Pharmacopeia (USP) quality standards across the industry—a move that would establish uniform benchmarks for ingredient purity, potency, and manufacturing practices. Currently, USP certification remains voluntary, and only a fraction of supplements on the market carry third-party quality verification.

Consumers can check whether their supplements meet quality standards using tools like PharmoniQ's Supplement Safety Checker, which evaluates products against multiple safety and quality criteria.

Industry Pushback and Competing Visions

The Natural Products Association (NPA) and Council for Responsible Nutrition (CRN), the industry's leading trade groups, have rejected the ACP's recommendations as unnecessary and potentially harmful to consumer access. Industry representatives argue that the current DSHEA framework, combined with FDA enforcement authority over adulterated and misbranded products, provides adequate consumer protection.

Trade groups point to several existing regulatory mechanisms:

• Current Good Manufacturing Practice (cGMP) requirements established in 2007
• FDA authority to remove unsafe products from the market
• New Dietary Ingredient (NDI) notification requirements for novel ingredients
• Adverse event reporting requirements implemented in 2007

Industry advocates also warn that premarket approval requirements could significantly limit product innovation and consumer choice while imposing substantial costs on smaller manufacturers. They argue that the voluntary third-party certification programs currently available—including NSF International, USP, and ConsumerLab—provide adequate quality assurance for consumers who seek it.

Implications for Manufacturers and Consumers

The ACP's position paper arrives at a pivotal moment for supplement regulation. Several factors are converging to create pressure for regulatory reform: growing consumer spending on supplements, increasing integration of supplements into conventional medical care, and ongoing quality concerns highlighted by academic research and media investigations.

For manufacturers, premarket approval requirements would represent a fundamental business model shift. Companies would need to invest in safety studies, clinical data generation, and regulatory submissions before launching products—similar to the requirements facing pharmaceutical manufacturers, though likely less stringent. Small and medium-sized businesses could face significant barriers to market entry.

For consumers, the impact would depend on implementation details. Stricter oversight could improve product quality and safety, but might also reduce product variety and increase prices. The tension between access and safety has long characterized supplement policy debates, and the ACP's recommendations bring this conflict into sharp focus.

Looking Ahead: Political and Regulatory Landscape

While the ACP's recommendations carry significant weight within the medical community, translating them into legislative or regulatory action faces substantial obstacles. DSHEA remains politically popular, with strong bipartisan support in Congress and backing from both industry and consumer advocacy groups who view supplements as an important part of personal health management.

Any significant changes to supplement regulation would require Congressional action, and previous attempts to strengthen FDA oversight have faced fierce resistance. The agency's current enforcement approach focuses on the most egregious violations—products containing pharmaceutical ingredients, supplements making disease treatment claims, or those linked to serious adverse events.

In the near term, the ACP's position paper is likely to intensify ongoing debates about supplement regulation rather than trigger immediate policy changes. However, it provides a detailed framework that other medical organizations, consumer advocates, or policymakers could reference in future regulatory discussions. For an industry built on the DSHEA framework for three decades, the growing chorus of voices calling for fundamental reform represents a significant shift in the regulatory landscape that stakeholders cannot afford to ignore.